Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review.

Current drug targets - 1 Jan 2016

Xie Yuanchao, Ogah Comfort Alicha, Jiang Xiangrui, Li Jianfeng, Shen Jingshan

Abstract excerpt

Nowadays, a large number of people in the world are suffering from chronic Hepatitis C. HCV NS5B polymerase conserved across the identified 7 HCV genotypes is considered to be the most promising target in combating HCV. During the past decade, significant progress has been made in the discovery of novel nucleoside HCV NS5B polymerase inhibitors. A potent anti-HCV drug, sofosbuvir with high cure rates has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Design
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Sofosbuvir

Share to Structure-Activity Relationship

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 26648061
DOI: 10.2174/1389450117666151209123751

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review.PMID 26648061Read ↗

Hepatitis C therapy with HCV NS5B polymerase inhibitors.Semantic proximity Read ↗

Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5BSemantic proximity Read ↗

Update on different aspects of HCV variability: focus on NS5B polymerase.Semantic proximity Read ↗

Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy.Semantic proximity Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C.Semantic proximity Read ↗

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virusSemantic proximity Read ↗

Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.Semantic proximity Read ↗

2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.Semantic proximity Read ↗

Recent Progress in the Development of Inhibitors of the Hepatitis C Virus RNA-Dependent RNA PolymeraseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.